Tuesday, 3 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Legal & Regulatory

Ajanta Pharma Legal & Regulatory

Ajanta Pharma announced the conclusion of a US FDA inspection at its Paithan facility. The audit, conducted from April 13 to April 21, 2026, ended with five Form-483 observations. The company stated it will respond to the regulator within the stipulated timeline.

Source

BSE filing, NSE: AJANTPHARM. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Ajanta Pharma Ltd: key numbers

Share price
₹3,396.30
Market cap
₹42,440 Cr
Revenue (annual)
₹5,453 Cr
Net profit (annual)
₹1,056 Cr
P/E (TTM)
33.6×Sector 47.2×
Promoter holding
63.47%-0.01% QoQ
FII holding
7.62%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Ajanta Pharma Ltd

All →
12:55 IST BSE
Financial Results

Ajanta Pharma Q2 FY27 Results: Net Profit ₹388.1 Cr, Up 49.2% YoY

Ajanta Pharma Ltd reported revenue from operations of ₹1,794 Cr (+32.5% YoY) and net profit of ₹388.1 Cr (+49.2% YoY) for Q2 FY27.

Key figure
Net profit ₹388.1 Cr · +49.2% YoY

Other legal & regulatory announcements

All →